| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2579285 | Thérapie | 2010 | 7 Pages |
Abstract
The present paper reviews clinical evidence underlining the role of ivabradine in the management of patient with ischemic heart disease. Reduction in heart rate mediated by this selective If current inhibitor has been associated with anti-ischemic efficacy without any effect on haemodynamic or myocardial contractility. The antianginal efficacy of ivabradine is similar or superior to that of conventional anti-ischemic agents. Moreover combination therapy with ivabradine provides substantial benefit in patients already receiving beta-blocker. Prognostic efficacy of ivabradine is evaluated in a large program of studies, among which BEAUTIFUL in coronary patients with left ventricular dysfunction. The SIGNIFY study is ongoing in stable coronary patients without ventricular dysfunction. Furthermore the SHIFT trial will evaluate ivabradine benefits in heart failure patients, whatever the origin, ischemic or not.
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology, Toxicology and Pharmaceutics (General)
Authors
Atul Pathak, Alain Berdeaux, Paul Mulder, Christian Thuillez,